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Background: Nortriptyline and venlafaxine are commonly used antidepressants for treatment of depression in older
patients. Both drugs are metabolized by the polymorphic cytochrome P450-2D6 (CYP2D6) enzyme and guidelines
for dose adaptations based on the CYP2D6 genotype have been developed. The CYP2D6 Screening Among Elderly
(CYSCE) trial is designed to address the potential health and economic value of genotyping for CYP2D6 in optimizing
dose-finding of nortriptyline and venlafaxine.
Methods/Design: In a pragmatic randomized controlled trial, patients diagnosed with a major depressive disorder
according to the DSM-IV and aged 60 years or older will be recruited from psychiatric centers across the Netherlands.
After CYP2D6 genotyping determined in peripheral blood obtained by finger-prick, patients will be grouped into
poor, intermediate, extensive, or ultrarapid metabolizers. Patients with deviant genotype (that is poor, intermediate or
ultrarapid genotype) will be randomly allocated to an intervention group in which the genotype and dosing advice
is communicated to the treating physician, or to a control group in which patients receive care as usual. Additionally,
an external reference group of patients with the extensive metabolizer genotype is included. Primary outcome in all
groups is time needed to obtain an adequate blood level of the antidepressant drug. Secondary outcomes include
adverse drug reactions measured by a shortened Antidepressant Side-Effects Checklist (ASEC), and cost-effectiveness
of the screening.
Discussion: Results of this trial will guide policy-making with regard to pharmacogenetic screening prior to treatment
with nortriptyline or venlafaxine among older patients with depression.
Trial registration: ClinicalTrials.gov: NCT01778907; registration date: 22 January 2013.
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Depressive disorder is a chronic disease with a consider-
able impact on mental and physical health as well as
quality of life [1]. The 1-month prevalence of major de-
pressive disorder (MDD) in the Dutch population (aged
55 to 85 years) is estimated around 2.0% [2]. From a
meta-analysis (studies included from 1999 to 2009) a
higher point prevalence estimation of 7.2 % has been re-
ported for late life depression (75+ years) [3]. Among
all mental diseases, MDD is ranked as a very disabling
disease [4] and depressive disorders are projected to be
the largest cause for disability by 2030 in high-income
countries [5].
MDD can be treated with antidepressants, which are
classified into different groups: selective serotonin re-
uptake inhibitors (SSRIs), tricyclic antidepressant (TCAs)
and others (for example,. selective serotonin-noradrenaline
reuptake inhibitors (SNRIs), mirtazapine, monoamine
oxidase inhibitors). Although overall efficacy estimates
are virtually similar between these drug groups, adverse
drug profiles differ [6]. Worldwide, clinical guidelines
usually advise first-step treatment with an SSRI because
of a more favorable adverse effect profile compared to
other antidepressants (for example, fewer cardiac side-
effects and often lower drug anticholinergic side-effects)
[7,8]. If the chosen SSRI is not effective, switching to a
TCA, preferably nortriptyline, or an SNRI, mostly venlafax-
ine, is an option [7].
Venlafaxine and nortriptyline are both metabolized
by the polymorphic cytochrome P450 (CYP2D6) iso-
enzyme [8]. Its polymorphic differences are generally
classified into four different phenotypes: poor metaboli-
zers (PM), intermediate metabolizers (IM), extensive
metabolizers (EM), and ultrarapid metabolizers (UM).
With respect to EM, PM and IM have a decreased en-
zymatic activity whereas UM have a higher activity,
which is described in more depth elsewhere [9]. As a re-
sult of the variation in metabolizing capacity, as well as
differences in gender, age, co-medication, and comorbid-
ity among patients, different pharmacokinetics are ob-
served [9,10]. These differences can be monitored by
therapeutic drug monitoring (TDM), which helps to find
the right dosage for an individual patient. TDM of nor-
triptyline is ‘strongly recommended’ and for venlafaxine
it is recommended especially during start of therapy
[11]. Prior and in addition to TDM, information about
the metabolic CYP2D6 activity could further improve
this dose-finding. Since it is possible to detect poly-
morphic differences of CYP2D6 based on genetic mater-
ial, it is not dependent on the actual antidepressant
intake (patient compliance) or collection time of the
sample, like TDM samples are.
For nortriptyline and venlafaxine genotyped-based dose
adjustment guidelines have been formulated [10,12,13]. Inthe Netherlands, the Royal Dutch Pharmacist Association
(KNMP) has made such guidelines available for current
clinical practice [14,15].
Despite the large number of studies that assessed the
relationship between pharmacogenetics and pharmaco-
kinetics of antidepressants, implementation of pharma-
cogenetic knowledge into clinical practice is still scarce.
The hypothesized clinical improvements facilitated by
genotype-based dose adjustments in addition to current
TDM, like improved efficacy and prevention of adverse
drug reactions, are still a matter of controversy and dis-
cussion [16,17]. There is a need to test this hypothesis in
daily clinical practice. Therefore, we designed a prag-
matic multicenter randomized controlled trial to deter-
mine the effects of a pharmacogenetic screening for
CYP2D6 on the time needed to obtain adequate blood
levels of nortriptyline or venlafaxine. Since older persons
are more vulnerable for adverse drug reactions, benefi-
cial effects of genotype adjusted dosing are expected to
be more apparent in this population. Therefore, the trial
is conducted among older depressed patients starting
with nortriptyline or venlafaxine. The cost-effectiveness
of this screening will be assessed to support decision-
making on the potential implementation of screening for
CYP2D6 genotype in daily clinical practice. The trial is




The study is a multicenter randomized controlled trial
across multiple old age psychiatry and geriatric mental
health care institutions in the Netherlands. Patients will
be recruited by their treating physician or a specialized
trial nurse. The study consists of two parts and for both
parts separate written informed consent will be obtained.
The first part is a basic genotype screening study in
which each eligible patient (see description in Partici-
pants below) starting with nortriptyline or venlafaxine
will be asked permission for genotyping. Patients with a
PM, IM and UM genotype will be selected for participa-
tion in the second (trial) part of the study. After giving
the second informed consent, the trial entails a follow-
up period of 6 weeks or longer in order to monitor the
blood levels and adverse reactions of either nortriptyline
or venlafaxine. A random selection of patients with an
EM genotype will be allocated to an additional reference
group (Figure 1). Recruitment is expected to be com-
pleted within approximately 3 years. If selected for the
trial part of the study, eligible patients are invited for a
baseline visit. At baseline, 2 weeks, and 4 weeks after
baseline blood samples are collected to estimate the
blood level of the drug by a ‘Dried Blood Spot’ (DBS)
method. Additionally, questionnaires concerning adverse
Figure 1 Flowchart for inclusion of patients.
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care use, and severity of depression are completed. Pa-
tients who do not complete dose-finding after 6 weeks
will be followed for additional 2-week measurements
until dose-finding is completed. These additional 2-week
samples will be collected only for those patients who
had a dose change 3 weeks or less prior to the moment
the sample was collected, since it can take up to 2 to
3 weeks for PMs of nortriptyline to reach steady state
concentration [19]. When the follow-up period is fin-
ished for an individual patient, the genotype information
will be supplied to the treating physician. Ethical approval
was obtained by an Independent Ethics Committee
(RTPO-Leeuwarden-NL; file number: NL40925.099.12)
and the study will be conducted in accordance with the
Declaration of Helsinki.
Participants
Patients 60 years or older and diagnosed with a major
depression according to the Diagnostic and Statistical
Manual of Mental Disorders, fourth edition text revision
(DSM-IV TR) [20], criteria (code: 296.2x or 296.3x) diag-
nosed by the treating physician, are eligible for inclusion.
Patients should be starting with either nortriptyline or ven-
lafaxine and competent to understand the two separate in-
formed consent procedures. Patients with known liver cell
damage, which in clinical practice often serves as a proxy
for a poor hepatic function (aspartate aminotransferase
and alanine aminotransferase (ASAT/ALAT) or gamma-
glutamyl transferase (γ-GT) ≥ twice the maximal reference
value), impaired renal function (eGFR < 30 mL/minute) in
combination with venlafaxine use, or currently using drugs
influencing blood levels of nortriptyline or venlafaxine are
excluded for trial participation. Patients using terbinafine,ketoconazole, voriconazole, kinidine, propafenon, cimeti-
dine, fluoxetine, paroxetine, bupropion, duloxetine, sertra-
line, abirateron, cinacalcet, rifampicine, and ritanovir are
excluded for trial participation. For these drugs, interac-
tions can be expected based on pharmacy interaction mon-
itoring software (G-standaard, Z-index BV, The Hague,
The Netherlands), summary of product characteristics, and
Flockhart’s interaction table [21].
CYP2D6 genotyping
In the first part of the study, a DBS sample for genotyp-
ing will be taken at the time of prescription of nortripty-
line or venlafaxine by means of a finger-prick [22]. The
sample will be sent to the Pharmacogenetic lab of the
Wilhelmina Hospital Assen (Assen, the Netherlands), for
analysis. Single nuclear polymorphism (SNPs) will be
assessed for the *3, *4, *5, *6, *10, *17, *41 alleles, as well
as duplications of the CYP2D6 gene. Presence of an al-
lele that completely lacks enzyme activity (*3, *4, *5, *6 )
paired with another allele completely lacking enzyme ac-
tivity results in a PM phenotype prediction and in an IM
phenotype prediction if paired with an allele with de-
creased enzyme activity (*10, *17, *41). Presence of only
one allele lacking enzyme activity, or two alleles with de-
creased enzyme activity also results in an IM phenotype
prediction. Duplications of the CYP2D6 gene results in
an UM phenotype prediction unless it is combined with
any allele with reduced or lacking enzyme activity. Du-
plications combined with any allele with reduced or
lacking enzyme activity results in exclusion of the pa-
tient from follow-up because no adequate dosing advice
can be given for these genotypes. After inclusion, genotype
information will be available for randomization within 6 to
9 days.
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Baseline assessment will include a severity of depression
score measured by the Montgomery-Asberg Depression
Rating Scale and measurement of symptoms which are
followed-up as adverse events during the further trial
[23]. In addition, comorbidities and drug use other than
nortriptyline and venlafaxine will be collected by the
Short Form Health and Labor Questionnaire [24].
Randomization and allocation
After the genotype is determined, patients with a PM,
IM, or UM genotype are selected and randomly allocated
by computer to the ‘deviating genotype-intervention arm’
(DG-I) or ‘deviating genotype-control arm’ (DG-C) for par-
ticipation in the main study (Figure 1). An additional sam-
ple of patients with the EM genotype is allocated to a third
‘normal genotype- control’ arm (NG-C). The PM, IM and
UM genotypes for CYP2D6 are expected to be found in ap-
proximately 30% of the population [9]. Therefore, it is ex-
pected that patients with the EM genotype will be found
more frequently than patients with a deviating genotype.
To prevent any potential time-dependent bias, the selec-
tion of patients with an EM genotype allocated to the
NG-C arm is dependent on the number of patients in
the other trial arms.
Deviating genotype-intervention arm (DG-I)
The DG-I arm includes patients with a PM, IM, or UM
genotype. The specific genotype accompanied by dosing
advice is directly communicated to the treating phys-
ician. This should preferably take place 14 days after in-
clusion. The dosing advice is based on the genotype and
drug only, meaning some standard advice depending on
these two variables is given by an automatically gener-
ated message (see Additional file 1).
Deviating genotype-control arm (DG-C) and normal
genotype-control arm (NG-C)
The DG-C arm includes patients with a deviating geno-
type and the NG-C arm will include patients with a nor-
mal genotype. In contrast to patients in the intervention
arm, the treating physician will not be informed about
the genotype of patients in one of the control arms. Al-
though methodologically there is a different approach
for deviating and normal genotype patients, for the
physician, patients will appears as one control group.
This ensures that patients in the control group can have
any genotype as in the normal population.
Outcomes
Primary outcome
Primary outcome will be the time needed to reach ad-
equate blood levels of nortriptyline or venlafaxine, which
will be determined by a DBS sample [25,26]. The use ofDBS for therapeutic drug monitoring is described in
more depth elsewhere [27]. Blood samples will be sent
to the Laboratory for Drug Analysis & Toxicology of the
Diaconessen Hospital (Meppel, the Netherlands). Advised
therapeutic ranges follow the current Dutch Clinical
Pharmacy guidelines (NVZA), indicating for nortriptyline
levels between 50 to 150 μg/L and for venlafaxine + O-
desmethylvenlafaxine between 100 to 400 μg/L. We
defined adequate drug levels as [1] being within the thera-
peutic range and [2] no dose changes during the previous
3 weeks.
Secondary outcome
Secondary outcomes will be adverse drug reactions mea-
sured by a shorter and modified version of the Anti-
depressant Side-Effect Checklist (ASEC) [28], quality of
life measured by the EuroQol 5D (EQ5D) [29], and
productivity and cost of health care use measured by the
Trimbos/iMTA questionnaire for Cost associated with
Psychiatric Illness (TiC-P) [24]. Severity of depression will
be measured to control for possible differences between
groups related to the severity of depression instead of the
genotype-based intervention, by the Quick Inventory of
Depressive Symptomatology Self-Reported Questionnaire
(QIDS-SR) [30]. Secondary outcomes will all be measured
by a telephone interview from baseline till endpoint, every
2 weeks, except for the side-effects. Side-effects will be
assessed by the treating physician and will additionally be
collected before start of the treatment. In this way we will
be able to correct for symptoms of depression or other
underlying physical diseases, which are often perceived by
the patient as side-effects of the antidepressant [28].
Sample size calculation
Based on clinical experience in the research setting it is
expected that on average it takes 4 weeks for patients
with a deviating genotype to reach adequate serum drug
levels. It is hypothesized that time to reach adequate
levels will be reduced by 50% (2 weeks) if we provide the
screening information to the physician within 6 to 9 days.
To obtain 90% power to detect a 50% reduction from 4
to 2 weeks (SD 3 weeks) with a type-1 error of 2.5% to ac-
count for multiple testing (within trial and externaltrial), a
minimum of 48 patients per arm is needed. To account for
loss to follow-up we intend to include at least 75 patients
per arm.
Statistical analysis and report
Reporting and analysis of the data from this trial will be
in accordance with the CONSORT 2010 guidelines [18].
Baseline
Baseline characteristics will be presented using descrip-
tive statistics including means or medians for continuous
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lytical statistics to estimate difference between the group
of patients who were lost to follow-up versus patients
who completed the trial as well as between the different
study arms will be determined by t-tests or non-parametric
alternatives for continuous variables and Chi-square tests
for categorical variables.
Primary analysis
The primary analysis will assess the mean time needed
to obtain adequate drug levels. The first time drug blood
levels are within the therapeutic range and dose is not
increased or decreased in the following 3 weeks is the
moment that is considered as the time needed to obtain
adequate drug levels. Mean differences in time to reach
adequate drug levels between trial groups will be esti-
mated using the t-test or a non-parametric alternative if
not normally distributed. Analysis of variance (ANOVA)
or Kruskal-Wallis test will be applied to test for potential
differences between the trial groups and the external ref-
erence group.
Secondary analyses
Secondary analysis will focus on statistical differences in
median number and severity scores of side-effects of
the drug. Since the side-effect profile is different for nor-
triptyline and venlafaxine, these analyses will be drug-
specific.
Cost-effectiveness analyses
Effects and costs will be determined from a societal per-
spective including both indirect and direct costs. Data
on health care associated resource use will be collected
and effects on productivity and quality of life (EQ5D)
will be investigated. To determine the incremental cost-
effectiveness ratio for intervention versus control strat-
egy from a societal perspective, guideline unit costs will
be linked to these resource use data. Incremental cost-
effectiveness will be calculated using state-of-the-art
methods including uncertainty analysis (bootstrapping,
Fieller’s estimates), scenario analysis, (probabilistic) sen-
sitivity analysis and presentation in cost-effectiveness ac-
ceptability curves.
Discussion
To the best of our knowledge, this is the first pragmatic
randomized controlled trial designed to test whether
CYP2D6 polymorphism genotyping among older de-
pressed patients starting with nortriptyline or venlafax-
ine in clinical practice adds value to regular care. Results
of this trial will generate evidence as to whether routinely-
based genotype testing can reduce the time needed for
dose-finding at the start of treatment and as a result reduce
adverse drug reactions.A possible limitation of this study is that the genotype
information is given to the physician after treatment
with the antidepressant has already been started for sev-
eral days. For the purpose of this trial, it would be ideal
to give the genotype information before treatment has
started. However, in clinical practice due to the urgency
of the disease, time between initiating a therapy with
nortriptyline or venlafaxine and actual start is limited.
Waiting for the genotype information before starting
pharmacotherapy could delay pharmacotherapy and is,
therefore, unwanted. Nevertheless, an effect of genotype
is still expected, because at start of treatment a low
dose is generally prescribed. When the treating phys-
ician has to evaluate therapy and to decide if the dos-
age should be increased, the genotype information will
be available [31].
Another limitation of this study is the study domain
represented by a heterogeneous group of severely de-
pressed patients, since the disease shows much variation
in symptomatology, severity and co-existing psychiatric
diseases like anxiety disorders and physical diseases, es-
pecially in secondary care [32]. However, a strict selec-
tion of patients who suffer from depression without the
presence of certain comorbid physical or psychiatric dis-
orders would exclude a lot of patients from this study
and limit applicability of the results to daily practice.
Therefore, inclusion is not limited by severity of depres-
sion, co-existing psychiatric diseases or other comorbidi-
ties. This is a common characteristic of pragmatic trials
and gives results which are better generalizable to actual
clinical practice [33].
Furthermore, the drug concentration-effect relation-
ship for venlafaxine is still a subject of debate [34]. This
is illustrated by different advised therapeutic windows.
Some refer to a therapeutic window between 250 to
750 μg/L, whereas recent guidelines advice a therapeutic
window between 100 to 400 μg/L, which is also incorpo-
rated in current Dutch guidelines [11,35]. Nevertheless,
current guidelines advise a smaller therapeutic window,
indicating the need for a more accurate drug dosing. To
facilitate this, genotyping may play an important role.
Strengths of this study are the random allocation of
subjects to receive genetic information that avoids in-
comparability of groups, strict protocolled design with
regular measurements, and a large number of patients to
detect statistically significant differences. We also in-
cluded an external control arm (NG-C) including pa-
tients with the EM genotype. This ensures physicians do
not know the genotype of control patients or that it de-
viates from EM.
The overall impact of CYP2D6 screening may be
underestimated in this trial, since the genotype is a life-
long characteristic and is, therefore, affecting the metab-
olism of many other drugs than the drugs studied in
Berm et al. Trials  (2015) 16:37 Page 6 of 7this trial. We only look at a short drug-specific time
effect in this study; however, it is not unlikely that patients
might benefit from their genotype information during fur-
ther pharmacotherapy.
Trial status
The recruitment of patients started in spring 2013 and is
expected to continue until spring 2016.
Additional file
Additional file 1: Advice based on the Dutch KNMP’s
pharmacogenetic guidelines, specified for this specific study
purpose with the help of experts in the field. Description: this
file contains the advice that was communicated to the treating
physicians during the study period.
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